DK1691805T3 - Anvendelse af urocansyre som er i stand til at omdanne celle cytoplasm til syre - Google Patents

Anvendelse af urocansyre som er i stand til at omdanne celle cytoplasm til syre

Info

Publication number
DK1691805T3
DK1691805T3 DK04798326T DK04798326T DK1691805T3 DK 1691805 T3 DK1691805 T3 DK 1691805T3 DK 04798326 T DK04798326 T DK 04798326T DK 04798326 T DK04798326 T DK 04798326T DK 1691805 T3 DK1691805 T3 DK 1691805T3
Authority
DK
Denmark
Prior art keywords
acid
cell cytoplasm
agent
urocanoic
converting cell
Prior art date
Application number
DK04798326T
Other languages
Danish (da)
English (en)
Inventor
Lasse Leino
Jarmo Laihia
Original Assignee
Biocis Pharma Oy
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=29763491&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=DK1691805(T3) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Biocis Pharma Oy filed Critical Biocis Pharma Oy
Application granted granted Critical
Publication of DK1691805T3 publication Critical patent/DK1691805T3/da

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/415—1,2-Diazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Immobilizing And Processing Of Enzymes And Microorganisms (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
DK04798326T 2003-12-09 2004-11-26 Anvendelse af urocansyre som er i stand til at omdanne celle cytoplasm til syre DK1691805T3 (da)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
FI20031793A FI20031793A0 (fi) 2003-12-09 2003-12-09 Uusi anti-proliferatiivinen farmaseuttinen koostumus
PCT/FI2004/000717 WO2005056007A1 (en) 2003-12-09 2004-11-26 The use of urocanic acid being able to acidify the cell cytoplasm and for preventing or halting cellular proliferation in a person

Publications (1)

Publication Number Publication Date
DK1691805T3 true DK1691805T3 (da) 2008-10-06

Family

ID=29763491

Family Applications (1)

Application Number Title Priority Date Filing Date
DK04798326T DK1691805T3 (da) 2003-12-09 2004-11-26 Anvendelse af urocansyre som er i stand til at omdanne celle cytoplasm til syre

Country Status (17)

Country Link
US (2) US20060189691A1 (de)
EP (1) EP1691805B1 (de)
JP (1) JP4825680B2 (de)
CN (1) CN1889950B (de)
AT (1) ATE396723T1 (de)
AU (1) AU2004296570B2 (de)
CA (1) CA2544720C (de)
CY (1) CY1108163T1 (de)
DE (1) DE602004014187D1 (de)
DK (1) DK1691805T3 (de)
ES (1) ES2303113T3 (de)
FI (1) FI20031793A0 (de)
PL (1) PL1691805T3 (de)
PT (1) PT1691805E (de)
SI (1) SI1691805T1 (de)
WO (1) WO2005056007A1 (de)
ZA (1) ZA200602940B (de)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FI20030379A0 (fi) * 2003-03-14 2003-03-14 Lasse Leino Uusi farmaseuttinen koostumus

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5455036A (en) * 1990-06-29 1995-10-03 Bode Chemie Method of using cis-urocaninic acid for topically treating psoriasis
EP0467116B2 (de) 1990-06-29 2001-12-05 Gs Development Ab Dermatologische Zusammensetzungen mit einem Gehalt an cis-Urocaninsäure
DE4122497C2 (de) 1991-07-02 1998-03-26 Wogepharm Gmbh Verwendung von trans-Urokaninsäure bei der prophylaktischen Therapie der Psoriasis
CA2114968A1 (en) * 1993-02-25 1994-08-26 John Wille Transdermal treatment with mast cell degranulating agents for drug-induced hypersensitivity
US5843979A (en) * 1993-02-25 1998-12-01 Bristol-Myers Squibb Company Transdermal treatment with mast cell degranulating agents for drug-induced hypersensitivity
GB9306473D0 (en) * 1993-03-29 1993-05-19 Bioglan Lab Ltd Pharmaceutically useful compounds
US5686100A (en) * 1994-11-22 1997-11-11 E.R. Squibb & Sons, Inc. Prophylactic and therapeutic treatment of skin sensitization and irritation
US5576013A (en) * 1995-03-21 1996-11-19 Eastern Virginia Medical School Treating vascular and neoplastic tissues
AU3309097A (en) * 1996-06-12 1998-01-07 Alza Corporation Reduction of skin sensitization in electrotransport drug delivery
DE19638064C2 (de) * 1996-09-18 1998-08-20 Voith Turbo Kg Verfahren zur Steuerung von Schaltvorgängen bei einem Fahrzeuggetriebe
DE19817295A1 (de) * 1998-04-18 1999-10-21 Beiersdorf Ag Kosmetische oder dermatologische Zubereitungen mit einem Gehalt an unsymmetrisch substituiertenTriazinderivaten zum Erhalt des Urocaninsäurestatus der Haut
US6420378B1 (en) * 1999-10-15 2002-07-16 Supergen, Inc. Inhibition of abnormal cell proliferation with camptothecin and combinations including the same
US6939541B2 (en) * 2000-04-14 2005-09-06 University Of South Carolina Cloning, overexpression and therapeutic use of bioactive histidine ammonia lyase
US6582734B1 (en) 2000-07-20 2003-06-24 Ecolab Inc. Antimicrobial composition useful for the treatment of bovine mastitis
US6541509B2 (en) * 2000-09-15 2003-04-01 Albert Einstein College Of Medicine Of Yeshiva University Method for treating neoplasia using combination chemotherapy
FI20030379A0 (fi) * 2003-03-14 2003-03-14 Lasse Leino Uusi farmaseuttinen koostumus

Also Published As

Publication number Publication date
ZA200602940B (en) 2007-07-25
PT1691805E (pt) 2008-06-12
CA2544720C (en) 2012-01-03
US20060189691A1 (en) 2006-08-24
US20060189692A1 (en) 2006-08-24
ATE396723T1 (de) 2008-06-15
WO2005056007A1 (en) 2005-06-23
AU2004296570A1 (en) 2005-06-23
AU2004296570B2 (en) 2011-01-06
JP4825680B2 (ja) 2011-11-30
CN1889950B (zh) 2011-02-09
FI20031793A0 (fi) 2003-12-09
SI1691805T1 (sl) 2008-08-31
ES2303113T3 (es) 2008-08-01
CY1108163T1 (el) 2014-02-12
CN1889950A (zh) 2007-01-03
US8338475B2 (en) 2012-12-25
JP2007513927A (ja) 2007-05-31
CA2544720A1 (en) 2005-06-23
EP1691805A1 (de) 2006-08-23
DE602004014187D1 (de) 2008-07-10
PL1691805T3 (pl) 2008-11-28
EP1691805B1 (de) 2008-05-28

Similar Documents

Publication Publication Date Title
NO20051854L (no) Vedvarende frigivelse opioidformuleringer og fremgangsmater for anvendelse.
TR199901417T2 (xx) Analjezik etkisi olan yeni bile�imler.
NO20064670L (no) Galeniske formuleringer av organiske forbindelser
SE0401345D0 (sv) Therapeutic compounds: Pyridine as scaffold
NO20062504L (no) Sammensetninger og doseringsformer for forbedret absorpsjon
MY144659A (en) 2-hydroxy-3-heteroarylindole derivatives as gsk3 inhibitors
SE9900961D0 (sv) Novel compounds
MX2009004203A (es) Combinaciones de paracetamol/ibuprofeno y metodo para su uso.
DK1487829T3 (da) Thiadizolylpiperazinderivater, der er nyttige til behandling eller forebyggelse af smerte
TW200603787A (en) Topical preparations containing ambroxol
BR0308212A (pt) Composto, composição farmacêutica, e, uso de um composto
RS54050B1 (en) FORMULATIONS AND METHODS FOR THE TREATMENT OF AMYLOIDOSIS
SE0402762D0 (sv) Indazole sulphonamide derivatives
SE9802208D0 (sv) Novel compounds
DK1492773T3 (da) 4-(Heterocyclyl)-benzensulfoximin-forbindelser til behandling af inflammation
CL2009001267A1 (es) Compuestos derivados de triciclos nitrogenados, con actividad antibacteriana; procedimiento de preparacion; composicion farmceutica que los comprende; para el tratamiento de la tuberculosis.
DK1150704T3 (da) Melagatran til behandling af betændelse
SE9802209D0 (sv) Novel compounds
NZ547376A (en) Transdermal pharmaceutical spray formulations comprising a VP/VA copolymer and a non-aqueous vehicle
DE60127839D1 (de) Pflaster mit 4-biphenylessigsäure
TW200503709A (en) Itching treating agent containing piperidine derivative as active ingredient
DK1691805T3 (da) Anvendelse af urocansyre som er i stand til at omdanne celle cytoplasm til syre
BR0011880A (pt) Método para o tratamento de condições co-mórbidas associadas com obesidade, composto, produto, uso de um composto, e, composição farmacêutica
CY1107346T1 (el) Φαρμακευτικη συνθεση για την ενδοκυτταρια οξινιση με cis-ουροκανικο οξυ
ECSP045210A (es) 2' - halo - 3' , 5' - dialcoxi - fen - 1' - il - imino - 2 -imidazolidinas y su uso como un fármaco